<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585388</url>
  </required_header>
  <id_info>
    <org_study_id>GINECO-BR112</org_study_id>
    <nct_id>NCT02585388</nct_id>
  </id_info>
  <brief_title>Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.</brief_title>
  <acronym>CHEOPS</acronym>
  <official_title>A Randomized Phase II, Multicenter Study Evaluating the Benefit of Adding a Non Steroidal Aromatase Inhibitor to Oral Vinorelbine in Patients With Pretreated Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase
      and metronomic chemotherapy treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase
      and metronomic chemotherapy treatment that would have the theoretical advantage of being well
      tolerated and more effective than chemotherapy alone even after an anti-aromatase therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Proportion of progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of partial and complete response rate by RECIST 1.1</measure>
    <time_frame>up to 6 months</time_frame>
    <description>partial and complete response rate by RECIST 1.1 in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>duration of response is defined as the time from randomization and the disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit after 24 weeks of treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>the clinical benefit is defined by the rate of complete response, by the rate of partial response and by the stability of lesions at 24 weeks according to criteria RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>the overall survival of patients randomized is defined as the time from randomization and the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to criteria NCI CTAEv4.03</measure>
    <time_frame>up to 2 years</time_frame>
    <description>tolerance of the treatment based on AE occurrence according to criteria NCI CTAEv4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life</measure>
    <time_frame>up to 2 years</time_frame>
    <description>health-related quality of life and symptomatic state will be evaluated by filling a questionnaire by patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vinorelbine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vinorelbine+Anastrozole or Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
And:
Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued</description>
    <arm_group_label>Vinorelbine</arm_group_label>
    <arm_group_label>Vinorelbine+Anastrozole or Letrozole</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Lestrozole at 2,5 mg every day , per oral</description>
    <arm_group_label>Vinorelbine+Anastrozole or Letrozole</arm_group_label>
    <other_name>ARM A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Anastrozole at 1 mg every day, per oral</description>
    <arm_group_label>Vinorelbine+Anastrozole or Letrozole</arm_group_label>
    <other_name>ARM B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 50 years.

          2. Histologically proven breast cancer.

          3. Progesterone and /or oestrogene receptors positive.

          4. HER2 negative on primary tumour.

          5. Patient taking hormonotherapy, in progression, already treated by at least one line of
             anti-aromatase non-steroidal hormonotherapy and by at least on line of chemotherapy.

          6. Patient having to begin a second or third line of chemotherapy.

          7. Presence of one or several measurable(s) or assessable(s) metastatic lesion(s).In case
             of isolated bone lesion (s): need to have a non-irradiated with an osteolytic
             component for be considered as lesion (s) target (s) and having an elevation of the
             CA15-3.

          8. Post menopausal woman.

          9. ECOG 0, 1 or 2.

         10. Adequate biological function.

               -  Neutrophil ≥ 1,5.E9/L

               -  Platelets ≥ 100.E9/L

               -  Creatinine clearance ≥ 30 mL/min

               -  Total bilirubin ≤ 1,5 x the upper limit of normal (ULN)

               -  Alkaline phosphatase ≤ 2,5 x ULN

               -  ALT, AST ≤ 1,5 x ULN in the absence of liver metastases or ≤ 3 x ULN if liver
                  metastases.

         11. Patient with a life expectancy greater than 3 months.

         12. Signed informed consent before enrollment.

         13. affiliation to a social security scheme

        Exclusion Criteria:

          1. Patient with located or single metastatic tumoral relapse, accessible to a surgical
             treatment.

          2. Patient having already received more 2 lines of chemotherapy for metastatic or
             advanced decease

          3. Patient having already received a treatment by Navelbine®

          4. Patient requiring an immediate located radiotherapy for analgesic action

          5. Patient with non-irradiated cerebral or symptomatic metastasis, symptomatic pulmonary
             carcinomatosis lymphangitis

          6. Simultaneous administration of another chemotherapy hormonotherapy or anti-tumoral
             drug

          7. Patient having already received another treatment ongoing evaluation within the 30
             days before the screening visit

          8. Known positive serology HIV

          9. Previous cancer within 5 years before the entry in the study, excepted an in situ
             carcinoma of the cervix or a spino or basal cell carcinoma of the skin or a
             nonmelanoma skin cancer with an adequate treatment.

         10. Any serious concomitant pathology and / or uncontrolled could compromise participation
             in the study (including uncontrolled diabetes, uncontrolled hypertension, severe
             infection, profound malnutrition, unstable angina or congestive heart failure - class
             III or IV according to the New York Heart Association - ventricular arrhythmias,
             progressive coronary artery disease, myocardial infarction within the last six months,
             chronic liver or kidney disease, a progressive ulceration of the digestive tract
             above, CNS disorders).

         11. Disorder of gastrointestinal function (GI) or pathology likely to significantly
             interfere with the absorption of Navelbine, of Letrozole or Anastrozole (eg.
             Ulcerative disease, uncontrolled nausea, vomiting, diarrhea, syndrome malabsorption,
             or resection of the small intestine).

         12. Known hypersensitivity to letrozole, anastrozole, vinorelbine or other vinco-alkaloids
             or any other component.

         13. Patient with fructose intolerance, galactose, a Lapp lactase deficiency or
             malabsorption of glucose and galactose (rare hereditary disease).

         14. Patient with a history of poor compliance with medical treatment.

         15. Patient can not be monitored regularly for family reasons, geographical, social or
             psychological.

         16. Patient with altered mental status would not allow him to understand the study or give
             informed consent .
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Etienne HEUDEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Agglomération Montargoise</name>
      <address>
        <city>Amilly</city>
        <zip>45207</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Fleyriat</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <zip>01000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Léman</name>
      <address>
        <city>Contamine sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Dracénie</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal des Alpes du Sud</name>
      <address>
        <city>Gap</city>
        <zip>05007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Drôme Ardèche - Clinique Pasteur</name>
      <address>
        <city>Guilherand-granges</city>
        <zip>07500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Drôme Ardèche</name>
      <address>
        <city>Guilhérand-Granges</city>
        <zip>07500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Laon</name>
      <address>
        <city>Laon</city>
        <zip>02000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Chartres Hôpital Louis Pasteur</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Layne</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Montélimar</name>
      <address>
        <city>Montélimar</city>
        <zip>26216</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oracle</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital privé des côtes d'armor</name>
      <address>
        <city>Plerin sur mer</city>
        <zip>22191</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy-Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Région d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer Courlancy Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Romans sur Isère</name>
      <address>
        <city>Romans sur Isère</city>
        <zip>26100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Drôme Nord - Site de Romans</name>
      <address>
        <city>Romans-sur-isere</city>
        <zip>26100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHP Saint Grégoire</name>
      <address>
        <city>Saint Grégoire</city>
        <zip>35750</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Soissons</name>
      <address>
        <city>Soissons</city>
        <zip>02200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Gauducheau</name>
      <address>
        <city>St Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Côte Basque Sud</name>
      <address>
        <city>St Jean de Luz</city>
        <zip>64501</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du Léman</name>
      <address>
        <city>Thonon-Les-Bains</city>
        <zip>74200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Jean Bernard</name>
      <address>
        <city>Valencienne</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pretreated metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

